title: Which treatment for hyperprolactinemic females?
abstract: This paper has as its first aim the review of the present evidence for risks of chronic hyperprolactinemia as well as benefits and hazards of treatment tools. Among long-term risks, an increased incidence of breast cancer is unlikely while growth of pituitary adenomas occur in a minority. Though control of prolactin secretion can be obtained in most cases, cure of the disease is estimated to be nil with dopaminergic drugs and less than 50% with pituitary surgery. The efficacy of radiotherapy remains questionable. The choice of short- and long-term treatment is discussed according to specific clinical conditions.
mesh_terms: D000236:Adenoma / Q000150:complications / Q000601:surgery*; D001971:Bromocriptine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000209:etiology / Q000628:therapy*; D010053:Ovary / Q000503:physiopathology; D010911:Pituitary Neoplasms / Q000150:complications / Q000601:surgery*; D012306:Risk
chemical_list: D001971:Bromocriptine